Mirum Pharmaceuticals Reports Q3 Revenue Beat Amid GAAP EPS Miss
Mirum Pharmaceuticals (MIRM) reported third-quarter financial results characterized by strong top-line growth but significant bottom-line losses. The company achieved revenue of $185.7 million, representing a 39.6% increase year-over-year and exceeding analyst expectations by $7.66 million. Despite the revenue beat, Mirum reported a GAAP earnings per share (EPS) of -$0.87, missing consensus estimates by $0.38. On the balance sheet, the company showed improved liquidity, reporting $500.5 million in unrestricted cash, cash equivalents, and investments as of September 30, 2026, up from $391.4 million at the end of 2025.
Tickers: $MIRM
Topics: cash position earnings miss revenue beat